Privigen Liquid
NDC Package 44206-439-40

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Privigen (human immunoglobulin g) liquids is a medication used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. This formulation utilizes a liquid delivery system. Marketed by Csl Behring Ag, this product is identified by NDC 44206-439 and is authorized under FDA application BLA125201.

Identification & Billing

NDC Package Code
44206-439-40
Package Description
1 VIAL, GLASS in 1 CARTON / 400 mL in 1 VIAL, GLASS (44206-439-93)
Product Code
44206-439
11-Digit Billing Format
44206043940
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Privigen
Non-Proprietary Name
Human Immunoglobulin G
Substance Name
Human Immunoglobulin G
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
HUMAN IMMUNOGLOBULIN G 40 g/400mL
Pharmacologic Class
Usage Information
This medication is used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. This medication is made from healthy human blood that has a high level of certain defensive substances (antibodies), which help fight infections. It is also used to increase the blood count (platelets) in persons with a certain blood disorder (idiopathic thrombocytopenia purpura-ITP). Platelets are needed to stop bleeding and form blood clots. Some immune globulin products may also be used to treat a certain type of muscle weakness problem (multifocal motor neuropathy) or a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). Some products may also be used to prevent certain blood vessel disorders in people with Kawasaki syndrome.

Regulatory & Marketing

Labeler Name
Csl Behring Ag
Product Type
Plasma Derivative
FDA Application #
BLA125201
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
01-20-2009
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J1459
Source: PDAC
INJECTION, IMMUNE GLOBULIN (PRIVIGEN), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID), 500 MG
HCPCS Dosage 500 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 44206-439-40 identifies a specific commercial package of 1 vial, glass in 1 carton / 400 ml in 1 vial, glass (44206-439-93) of Privigen, a plasma derivative labeled by Csl Behring Ag. This liquid is formulated for intravenous use and contains human immunoglobulin g as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Csl Behring Ag on January 20, 2009. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. This medication is made from healthy human blood that has a high level of certain defensive substances (antibodies), which help fight infections. It is also used to increase the blood count (platelets) in persons with a certain blood disorder (idiopathic thrombocytopenia purpura-ITP). Platelets are needed to stop bleeding and form blood clots. Some immune globulin products may also be used to treat a certain type of muscle weakness problem (multifocal motor neuropathy) or a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). Some products may also be used to prevent certain blood vessel disorders in people with Kawasaki syndrome.

How is this Csl Behring Ag product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 44206043940. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
44206-439-40
11-Digit CMS (5-4-2)
44206-0439-40

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.